RNAi therapies: Drugging the undruggable

Science Translational Medicine

Volumn 6, Issue 240, 2014, Pages

  Wu, Sherry Y ^a   Lopez Berestein, Gabriel ^a   Calin, George A ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; AGN 211745; ALN AT3SC; ALN TTR 01; ALN TTR 02; ALN TTRSC; ALN VSP 02; ANTIASTHMATIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ARC 520; ASVASIRAN; ATU 027; BEVASIRANIB; CALAA 01; DERMATOLOGICAL AGENT; EXCELLAIR; LIPID NANOPARTICLE; MESSENGER RNA; NANOCARRIER; NANOPARTICLE; PF 655; QP 1007; RX I 109 CTFG; SMALL INTERFERING RNA; SYL 001; SYL 040012; TD 101; TKM PLK 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; AMYLOIDOSIS; ASTHMA; CANCER PATIENT; CANCER THERAPY; CONGENITAL PACHYONYCHIA; DNA CLEAVAGE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG UPTAKE; EYE DISEASE; FEASIBILITY STUDY; GENE EXPRESSION; GENE SILENCING; HEMOPHILIA; HIGH THROUGHPUT SCREENING; HUMAN; INTRACELLULAR TRANSPORT; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PARTICLE SIZE; PATIENT CARE; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SCAR; SIGNAL TRANSDUCTION; SOLID TUMOR; STUDY DESIGN; SURFACE CHARGE; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; VIRUS INFECTION; GENE THERAPY; GENETICS; NEOPLASMS; PHYSIOLOGY; PROCEDURES;

GENETIC THERAPY; HUMANS; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84903133224     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008362     Document Type: Review

References (30)

1. J. Tabernero, G. I. Shapiro, P. M. LoRusso, A. Cervantes, G. K. Schwartz, G. J. Weiss, L. Paz-Ares, D. C. Cho, J. R. Infante, M. Alsina, M. M. Gounder, R. Falzone, J. Harrop, A. C. White, I. Toudjarska, D. Bumcrot, R. E. Meyers, G. Hinkle, N. Svrzikapa, R. M. Hutabarat, V. A. Clausen, J. Cehelsky, S. V. Nochur, C. Gamba-Vitalo, A. K. Vaishnaw, D. W. Sah, J. A. Gollob, H. A. Burris 3rd, First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3, 406-417 (2013).
2. T. Golan, A. Hubert, A. Shemi, A. Segal, A. Dancour, E. Z. Khvalevsky, "A phase I trial of a local delivery of siRNA against k-ras in combination with chemotherapy for locally advanced pancreatic adenocarcinoma," paper presented at the 49th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL (2013).
3. M. E. Davis, J. E. Zuckerman, C. H. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel, A. Ribas, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).
4. T. Coelho, D. Adams, A. Silva, P. Lozeron, P. N. Hawkins, T. Mant, J. Perez, J. Chiesa, S. Warrington, E. Tranter, M. Munisamy, R. Falzone, J. Harrop, J. Cehelsky, B. R. Bettencourt, M. Geissler, J. S. Butler, A. Sehgal, R. E. Meyers, Q. Chen, T. Borland, R. M. Hutabarat, V. A. Clausen, R. Alvarez, K. Fitzgerald, C. Gamba-Vitalo, S. V. Nochur, A. K. Vaishnaw, D. W. Sah, J. A. Gollob, O. B. Suhr, Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819-829 (2013).
5. D. Strumberg, B. Schultheis, U. Traugott, C. Vank, A. Santel, O. Keil, K. Giese, J. Kaufmann, J. Drevs, Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int. J. Clin. Pharmacol. Ther. 50, 76-78 (2012).
6. R. K. Ramanathan, S. I. Hamburg, M. J. Borad, M. Seetharam, M. N. Kundranda, P. Lee, P. Fredlund, M. Gilbert, C. Mast, S. C. Semple, A. D. Judge, B. Crowell, L. Vocila, I. MacLachlan, D. W. Northfelt, "A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors," paper presented at the 49th annual American Association for Cancer Research Meeting, Washington DC, 6 to 10 April, 2013.
7. A. Akinc, G. Battaglia, Exploiting endocytosis for nanomedicines. Cold Spring Harb. Perspect. Biol. 5, a016980 (2013).
8. H. Cabral, Y. Matsumoto, K. Mizuno, Q. Chen, M. Murakami, M. Kimura, Y. Terada, M. R. Kano, K. Miyazono, M. Uesaka, N. Nishiyama, K. Kataoka, Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 6, 815-823 (2011).
9. C. N. Landen Jr., A. Chavez-Reyes, C. Bucana, R. Schmandt, M. T. Deavers, G. Lopez-Berestein, A. K. Sood, Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910-6918 (2005).
10. D. Stirland, J. Nichols, T. Denison, Y. Bae, in Targeted Drug Delivery for Cancer Therapy. K. Park, Ed. (Woodhead Publishing, Cambridge, UK, 2014).
11. J. Mi, Y. Liu, Z. N. Rabbani, Z. Yang, J. H. Urban, B. A. Sullenger, B. M. Clary, In vivo selection of tumortargeting RNA motifs. Nat. Chem. Biol. 6, 22-24 (2010).
12. J. Bábíčková, L'. Tóthová, P. Boor, P. Celec, In vivo phage display - A discovery tool in molecular biomedicine. Biotechnol. Adv. 31, 1247-1259 (2013).
13. J. Gilleron, W. Querbes, A. Zeigerer, A. Borodovsky, G. Marsico, U. Schubert, K. Manygoats, S. Seifert, C. Andree, M. Stöter, H. Epstein-Barash, L. Zhang, V. Koteliansky, K. Fitzgerald, E. Fava, M. Bickle, Y. Kalaidzidis, A. Akinc, M. Maier, M. Zerial, Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31, 638-646 (2013).
14. C. I. Wooddell, D. B. Rozema, M. Hossbach, M. John, H. L. Hamilton, Q. Chu, J. O. Hegge, J. J. Klein, D. H. Wakefield, C. E. Oropeza, J. Deckert, I. Roehl, K. Jahn-Hofmann, P. Hadwiger, H. P. Vornlocher, A. McLachlan, D. L. Lewis, Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther. 21, 973-985 (2013).
15. S. C. Wong, J. J. Klein, H. L. Hamilton, Q. Chu, C. L. Frey, V. S. Trubetskoy, J. Hegge, D. Wakefield, D. B. Rozema, D. L. Lewis, Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid. Ther. 22, 380-390 (2012).
16. J. Soutschek, A. Akinc, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Elbashir, A. Geick, P. Hadwiger, J. Harborth, M. John, V. Kesavan, G. Lavine, R. K. Pandey, T. Racie, K. G. Rajeev, I. Röhl, I. Toudjarska, G. Wang, S. Wuschko, D. Bumcrot, V. Koteliansky, S. Limmer, M. Manoharan, H. P. Vornlocher, Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
17. T. Schluep, L. Kalinoski, C. I. Wooddell, D. L. Lewis, R. G. Gish, J. Lickliter, B. D. Given, I. Phase, "FIH clinical trial of ARC-520, an siRNA-based therapeutic for treatment of chronic HBV infection, in normal healthy volunteers," paper presented at the HepDART meeting, Hawaii (December 2013).
18. S. Y. Wu, X. Yang, K. M. Gharpure, H. Hatakeyama, M. Egli, M. H. McGuire, A. S. Nagaraja, T. M. Miyake, R. Rupaimoole, C. V. Pecot, M. Taylor, S. Pradeep, M. Sierant, C. Rodriguez-Aguayo, H. J. Choi, R. A. Previs, G. N. Armaiz-Pena, L. Huang, C. Martinez, T. Hassell, C. Ivan, V. Sehgal, R. Singhania, H. D. Han, C. Su, J. H. Kim, H. J. Dalton, C. Kovvali, K. Keyomarsi, N. A. J. McMillan, W. W. Overwijk, J. Liu, J. S. Lee, K. A. Baggerly, G. Lopez-Berestein, P. T. Ram, B. Nawrot, A. K. Sood, 2'-OMe-phosphorodithioate- modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat. Commun. 5, 3459 (2014).
19. K. T. Love, K. P. Mahon, C. G. Levins, K. A. Whitehead, W. Querbes, J. R. Dorkin, J. Qin, W. Cantley, L. L. Qin, T. Racie, M. Frank-Kamenetsky, K. N. Yip, R. Alvarez, D. W. Sah, A. de Fougerolles, K. Fitzgerald, V. Koteliansky, A. Akinc, R. Langer, D. G. Anderson, Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl. Acad. Sci. U.S.A. 107, 1864-1869 (2010).
20. L. B. Alexandrov, S. Nik-Zainal, D. C. Wedge, S. A. Aparicio, S. Behjati, A. V. Biankin, G. R. Bignell, N. Bolli, A. Borg, A. L. Børresen-Dale, S. Boyault, B. Burkhardt, A. P. Butler, C. Caldas, H. R. Davies, C. Desmedt, R. Eils, J. E. Eyfjörd, J. A. Foekens, M. Greaves, F. Hosoda, B. Hutter, T. Ilicic, S. Imbeaud, M. Imielinski, N. Jäger, D. T. Jones, D. Jones, S. Knappskog, M. Kool, S. R. Lakhani, C. López-Otín, S. Martin, N. C. Munshi, H. Nakamura, P. A. Northcott, M. Pajic, E. Papaemmanuil, A. Paradiso, J. V. Pearson, X. S. Puente, K. Raine, M. Ramakrishna, A. L. Richardson, J. Richter, P. Rosenstiel, M. Schlesner, T. N. Schumacher, P. N. Span, J. W. Teague, Y. Totoki, A. N. Tutt, R. Valdés-Mas, M. M. van Buuren, L. van 't Veer, A. Vincent-Salomon, N. Waddell, L. R. Yates, J. Zucman-Rossi, P. A. Futreal, U. McDermott, P. Lichter, M. Meyerson, S. M. Grimmond, R. Siebert, E. Campo, T. Shibata, S. M. Pfister, P. J. Campbell, M. R. Stratton, Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, ICGC PedBrain, Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
21. M. Steckel, M. Molina-Arcas, B. Weigelt, M. Marani, P. H. Warne, H. Kuznetsov, G. Kelly, B. Saunders, M. Howell, J. Downward, D. C. Hancock, Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res. 22, 1227-1245 (2012).
22. D. Etemadmoghadam, B. A. Weir, G. Au-Yeung, K. Alsop, G. Mitchell, J. George, S. Davis, A. D. D'Andrea, K. Simpson, W. C. Hahn, D. D. Bowtell, Australian Ovarian Cancer Study Group, Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc. Natl. Acad. Sci. U.S.A. 110, 19489-19494 (2013).
23. S. Beronja, P. Janki, E. Heller, W. H. Lien, B. E. Keyes, N. Oshimori, E. Fuchs, RNAi screens in mice identify physiological regulators of oncogenic growth. Nature 501, 185-190 (2013).
24. D. Schramek, A. Sendoel, J. P. Segal, S. Beronja, E. Heller, D. Oristian, B. Reva, E. Fuchs, Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science 343, 309-313 (2014).
25. M. Nishimura, E. J. Jung, M. Y. Shah, C. Lu, R. Spizzo, M. Shimizu, H. D. Han, C. Ivan, S. Rossi, X. Zhang, M. S. Nicoloso, S. Y. Wu, M. I. Almeida, J. Bottsford-Miller, C. V. Pecot, B. Zand, K. Matsuo, M. M. Shahzad, N. B. Jennings, C. Rodriguez-Aguayo, G. Lopez-Berestein, A. K. Sood, G. A. Calin, Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 3, 1302-1315 (2013).
26. C. Q. Mao, M. H. Xiong, Y. Liu, S. Shen, X. J. Du, X. Z. Yang, S. Dou, P. Z. Zhang, J. Wang, Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery. Mol. Ther. 22, 964-973 (2014).
27. M. Robbins, A. Judge, I. MacLachlan, siRNA and innate immunity. Oligonucleotides 19, 89-102 (2009).
28. M. A. Maier, M. Jayaraman, S. Matsuda, J. Liu, S. Barros, W. Querbes, Y. K. Tam, S. M. Ansell, V. Kumar, J. Qin, X. Zhang, Q. Wang, S. Panesar, R. Hutabarat, M. Carioto, J. Hettinger, P. Kandasamy, D. Butler, K. G. Rajeev, B. Pang, K. Charisse, K. Fitzgerald, B. L. Mui, X. Du, P. Cullis, T. D. Madden, M. J. Hope, M. Manoharan, A. Akinc, Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570-1578 (2013).
29. L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhal, M. J. Wood, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341-345 (2011).
30. H. Lee, A. K. Lytton-Jean, Y. Chen, K. T. Love, A. I. Park, E. D. Karagiannis, A. Sehgal, W. Querbes, C. S. Zurenko, M. Jayaraman, C. G. Peng, K. Charisse, A. Borodovsky, M. Manoharan, J. S. Donahoe, J. Truelove, M. Nahrendorf, R. Langer, D. G. Anderson, Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat. Nanotechnol. 7, 389-393 (2012).